Company profile
Zilico Ltd - Zilico Ltd
Zilico is developing the next generation of diagnostic devices that remove subjectivity, increase accuracy and deliver results in real-time.
Updated 06 Jun 2026 16:52
Reference milestones and recent Companies House filing stream events.
Next confirmation statement due date
Next accounts due date
SH01 | Transaction MzUxMjk4MDgzOGFkaXF6a2N4
Published 27 Mar 2026 13:24
Last confirmation statement made up date
Last accounts made up date
Company registered at Companies House
1 May 2019 to 30 Sep 2021
To apply expertise in dynamic frequency analysis and machine learning to allow Electrical Impedance Spectroscopy to be applied to new clinical areas in diagnosing cervical cancer.
1 Jul 2014 to 28 Feb 2015
When found at early stages of development, oral cancers have an 80 - 90 % survival rate. Unfortunately, the majority are found as late stage cancers. This accounts for the very high death rate of ~43% at five years from diagnosis, for all stages combined at time of diagnosis. Zilico Ltd is developing the next generation of cancer diagnostics and proposes ...
1 May 2014 to 31 Aug 2014
When found at early stages of development, oral cancers have an 80 - 90 % survival rate. Unfortunately, the majority are found as late stage cancers. This accounts for the very high death rate of ~43% at five years from diagnosis, for all stages combined at time of diagnosis. Zilico Ltd is developing the next generation of cancer diagnostics and proposes ...
